Medtronic Invests In Gene Therapy Delivery For Parkinson’s Disease
This article was originally published in The Gray Sheet
Executive Summary
Medtronic is extending its investment in gene therapy delivery to include neurological indications for Parkinson's disease and temporal lobe epilepsy under an agreement with Neurologix
You may also be interested in...
Medtronic Continues To Run (RNA) Interference With Biotech Firm Alnylam
Medtronic is upping its investment in biotech drug delivery by expanding its collaboration with Alnylam for development of an RNA-based treatment for Huntington's disease
Medtronic Continues To Run (RNA) Interference With Biotech Firm Alnylam
Medtronic is upping its investment in biotech drug delivery by expanding its collaboration with Alnylam for development of an RNA-based treatment for Huntington's disease
Heart Repair Venture Undeterred By Risk; Is “Biopacing” Next For Medtronic?
MG Biotherapeutics' initial focus on autologous cell repair of the heart, if successful, will give the joint venture a "commercial bridge" to further combination product development, Genzyme Exec VP Earl Collier said at Medtronic's annual investor conference Oct. 5